Find generic entry opportunities
Manage your formulary budget
Proactively manage your pharmacy inventory
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Anticipate generic drug launch
Drug patents …
… from Kazakhstan to Kalamazoo
|Title:||Guanidinothiazole compounds, process for preparation and gastric inhibiting compositions containing them|
|Abstract:||Novel guanidinothiazole compounds of the general formula ##STR1## wherein R represents a hydrogen atom or a lower alkyl group, R.sub.1 represents an amino group, a lower alkyl group, a halogeno lower alkyl group, a substituted- or unsubstituted-aryl group, a mono- or di-lower alkylamino group, an arylamino group or an aralkylamino group, R.sub.2 represents a hydrogen atom, a lower alkyl group, a lower alkenyl group or a lower alkynyl group, Y represents a sulfur atom or a methylene group, m and n, each represents an integer of 1-3, and the pharmacologically acceptable acid addition salts thereof, they are useful as gastric acid secretion inhibitors.|
|Inventor(s):||Hirata; Yasufumi (Omiya, JP), Yanagisawa; Isao (Tokyo, JP), Ishii; Yoshio (Omiya, JP), Tsukamoto; Shinichi (Tokyo, JP), Ito; Noriki (Twatsuki, JP), Isomura; Yasuo (Yokohama, JP), Takeda; Masaaki (Urawa, JP)|
|Assignee:||Yamanouchi Pharmaceutical Co., Ltd. (Tokyo, JP)|
Patent Claim Types:|
see list of patent claims
|Compound; Use; Composition;|
|Foriegn Application Priority Data|
|Foreign Country||Foreign Patent Number||Foreign Patent Date|
|Japan||54-98906||Aug 02, 1979|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.